3Aikawa N, Ishizaka A, Hirasawa H, et al. Reevaluation of the efficacy and safety of the neutrophil elastase inhibitor, sivelestat, for the treatment of acute lung injury associated with systemic inflammatory response syndrome; a phase IV study[ J]. Pulm Pharmacol Ther,2011 ,doil0. 1016/j. pupt. 2011.03. 001.
4Liang B A. FDA use of the black box warning: time for re-evaluation as a safety tool[ J ]. J Clin Anesth ,2002,14 ( 8 ) :598.
5Paul R Rosenbaum, Donald B Rubin. The central role of the propensity score in observational studies for causal effects [ J ]. Biometrika,1983, 1 (70) : 41.
6Inrbens G W, Angrist J D. Indentification and estimation of local average treatment effect[ J]. Econometrica, 1994, 62 : 467.
7D'Agostino R B. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group[ J]. Stat Med, 1998,17:2265.
8Rubin D B. Matching using estimated propensity scores: relating theory to practice[ J]. Biometrics, 1996, 52:249.
9Paul R, Rubin D B. Reducing bias in observational studies using subclassification on the propensity score [ J ]. J Am Star Assoc, 1984,79:516.
10Robins J M, Hernan M A, B rumback B. Marginal structural models and causal inference in epidemiology [ J ]. Epidemiology, 2000, 11:550.
